Evidence map›Paper›PMID 34940619›Full record

ArticleMetabolites2021

The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods.

Laura Canclini, Amir Mohammad Malvandi, Patrizia Uboldi, Najoua Jabnati, Liliana Grigore, Alberto Zambon, Andrea Baragetti, Alberico Luigi Catapano

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Laura CancliniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0001-8011-7441
Amir Mohammad MalvandiIRCCS Multimedica, 20138 Milan, Italy.ORCID 0000-0003-1243-2372
Patrizia UboldiDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Najoua JabnatiDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Liliana GrigoreIRCCS Multimedica, 20099 Sesto San Giovanni, Italy.
Alberto ZambonIRCCS Multimedica, 20099 Sesto San Giovanni, Italy.ORCID 0000-0001-7096-5201
Andrea BaragettiDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-6216-1999
Alberico Luigi CatapanoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-7593-2094
University of Milan · ITMultiMedica · IT

Funding

Cibo, Microbiota, Salute" by "Vini di Batasiolo S.p.A" AL_RIC19ABARA_01ERANET ER-2017-2364981Fondazione Cariplo 2015-0524Fondazione Cariplo 2015-0564H2020 REPROGRAM PHC-03-2015/667837-2Ministry of Health GR-2011-02346974PRIN 2017H5F943
6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin type-9 (PCSK9) is key regulator of low-density lipoprotein (LDL) metabolism. A significant proportion of PCSK9 is believed to be associated with LDL in plasma as it circulates, although this finding is still a matter of debate. The purpose of this study was to establish an experimental method to investigate the presence of such an interaction in the bloodstream. We compared a number of well-established methods for lipoprotein (LP) isolation to clarify whether PCSK9 associates differently to circulating lipoproteins, such as KBr gradient ultracentrifugation, physical precipitation of ApoB-LPs, fast protein liquid chromatography (FPLC) and iodixanol gradient ultracentrifugation. Our data show heterogeneity in PCSK9 association to lipoproteins according to the method used. Two methods, iodixanol ultracentrifugation and column chromatography, which did not involve precipitation or high salt concentration, consistently showed an interaction of PCSK9 with a subfraction of LDL that appeared to be more buoyant and have a lower size than average LDL. The percent of PCSK9 association ranged from 2 to 30% and did not appear to correlate to plasma or LDL cholesterol levels. The association of PCSK9 to LDL appeared to be sensitive to high salt concentrations. FPLC and iodixanol gradient ultracentrifugation appeared to be the most suitable methods for the study of this association.

Indexed as

atherosclerosiscardiovascular diseasesLDLlipidslipoproteinsPCSK9

Identifiers

PMID34940619
PMCPMC8706035
OpenAlexW4200517528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.